JP2019517596A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517596A5
JP2019517596A5 JP2019517187A JP2019517187A JP2019517596A5 JP 2019517596 A5 JP2019517596 A5 JP 2019517596A5 JP 2019517187 A JP2019517187 A JP 2019517187A JP 2019517187 A JP2019517187 A JP 2019517187A JP 2019517596 A5 JP2019517596 A5 JP 2019517596A5
Authority
JP
Japan
Prior art keywords
dicyano
thio
phenylacetamide
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517187A
Other languages
English (en)
Japanese (ja)
Other versions
JP7051829B2 (ja
JP2019517596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/053511 external-priority patent/WO2017216727A1/en
Publication of JP2019517596A publication Critical patent/JP2019517596A/ja
Publication of JP2019517596A5 publication Critical patent/JP2019517596A5/ja
Application granted granted Critical
Publication of JP7051829B2 publication Critical patent/JP7051829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517187A 2016-06-13 2017-06-13 Dnmt1の阻害剤としての置換ピリジン Active JP7051829B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662349227P 2016-06-13 2016-06-13
US62/349,227 2016-06-13
US201662393256P 2016-09-12 2016-09-12
US62/393,256 2016-09-12
US201662412343P 2016-10-25 2016-10-25
US62/412,343 2016-10-25
PCT/IB2017/053511 WO2017216727A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1

Publications (3)

Publication Number Publication Date
JP2019517596A JP2019517596A (ja) 2019-06-24
JP2019517596A5 true JP2019517596A5 (enExample) 2020-07-27
JP7051829B2 JP7051829B2 (ja) 2022-04-11

Family

ID=59239935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517187A Active JP7051829B2 (ja) 2016-06-13 2017-06-13 Dnmt1の阻害剤としての置換ピリジン

Country Status (20)

Country Link
US (1) US10975056B2 (enExample)
EP (1) EP3468953B1 (enExample)
JP (1) JP7051829B2 (enExample)
KR (1) KR20190017030A (enExample)
CN (1) CN109563043B (enExample)
AU (1) AU2017283790B2 (enExample)
CA (2) CA3026211A1 (enExample)
CL (1) CL2018003577A1 (enExample)
CO (1) CO2018013717A2 (enExample)
CR (1) CR20180580A (enExample)
DO (1) DOP2018000273A (enExample)
ES (1) ES2993451T3 (enExample)
IL (1) IL263163B (enExample)
JO (1) JOP20180120A1 (enExample)
MA (1) MA45244A (enExample)
MX (1) MX391600B (enExample)
PE (1) PE20190971A1 (enExample)
PH (1) PH12018502633B1 (enExample)
SG (1) SG11201809559UA (enExample)
WO (2) WO2017216727A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
SG10202008647TA (en) 2016-10-04 2020-10-29 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
KR102743630B1 (ko) 2017-03-28 2024-12-18 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
WO2018208667A1 (en) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. がん治療のためのベンゾ[b]チオフェンSTINGアゴニスト
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
TWI793294B (zh) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting促效劑化合物
FI3911647T3 (fi) 2019-01-15 2024-03-01 Gilead Sciences Inc Isoksatsoliyhdiste fxr-agonistina ja sitä käsittäviä lääkekoostumuksia
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
WO2022076563A1 (en) * 2020-10-07 2022-04-14 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
CN116917273A (zh) * 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 作为dnmt1抑制剂的经取代的吡啶
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药(香港)有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN113278021B (zh) * 2021-05-29 2022-09-23 天津全和诚科技有限责任公司 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法
EP4419075A1 (en) 2021-10-19 2024-08-28 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CN114230459A (zh) * 2021-12-10 2022-03-25 武汉九州钰民医药科技有限公司 一种化合物的制备方法及分析检测方法
WO2023192629A1 (en) * 2022-04-01 2023-10-05 Herophilus, Inc. Induction of mecp2 expression by dna methyl transferase inhibitors
WO2024156288A1 (en) * 2023-01-29 2024-08-02 Shanghai Kygent Pharmaceutical Co., Ltd Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications
WO2025006902A2 (en) * 2023-06-29 2025-01-02 Dana-Farber Cancer Institute, Inc. Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1)
WO2025085756A1 (en) * 2023-10-18 2025-04-24 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
WO2025190285A1 (en) * 2024-03-12 2025-09-18 Shanghai Kygent Pharmaceutical Co., Ltd Pyridine compounds, pharmaceutical compositions, and applications
CN119306700A (zh) * 2024-08-28 2025-01-14 山东大学 Dnmt1-hdac双靶点抑制剂及其制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875C (en) 1990-11-26 2002-07-02 Alan R.P. Paterson Methods and probes for detecting nucleoside transporter and method for producing the probes
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
WO1994022853A1 (en) 1993-03-26 1994-10-13 Shell Internationale Research Maatschappij B.V. Herbicidal 1-heteroaryl pyrazolidin-3,5-diones
AU1295597A (en) 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
JP2000502708A (ja) 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US20020052343A1 (en) 1999-12-15 2002-05-02 Allen Darin Arthur Salicylamides as serine protease inhibitors
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
TW200406370A (en) 2002-06-28 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives
AR043048A1 (es) 2002-08-30 2005-07-13 Syngenta Participations Ag Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
TW200410632A (en) 2002-12-11 2004-07-01 Syngenta Participations Ag Dihalo-allyloxy-phenol derivatives having pesticidal activity
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
AU2004230928B2 (en) 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
CA2539707C (en) 2003-09-23 2011-08-09 Merck & Co., Inc. Quinoline potassium channel inhibitors
AU2011253934C1 (en) 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1655296A1 (en) 2004-10-25 2006-05-10 Graffinity Pharmaceuticals AG Thrombin inhibitors
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP2030971B1 (en) 2006-06-20 2011-10-12 Ishihara Sangyo Kaisha, Ltd. Pest control agent containing novel pyridyl-methanamine derivative or salt thereof
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
US7799781B2 (en) 2007-02-01 2010-09-21 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009034433A2 (en) 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
AU2008310519B2 (en) 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
TW201028381A (en) * 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
UY32055A (es) 2008-08-19 2010-03-26 Astrazeneca Ab Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
KR101146010B1 (ko) * 2009-09-10 2012-05-16 서울대학교산학협력단 TNF-α 매개성 질환의 예방 및 치료용 조성물
EP2500344A4 (en) 2009-11-13 2013-05-01 Shionogi & Co AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION
RU2636589C2 (ru) 2009-12-23 2017-11-24 ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Аминопиримидиновые ингибиторы киназ
EP3489236B1 (en) 2009-12-23 2020-09-30 Takeda Pharmaceutical Company Limited Process for the preparation of fused heteroaromatic pyrrolidinones
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2011103289A2 (en) 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013019635A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2736329A4 (en) 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CA2886495C (en) 2012-09-28 2023-09-19 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c
JP2017502968A (ja) 2014-01-21 2017-01-26 ウォックハート リミテッド 7−オキソ−1,6−ジアザビシクロ[3.2.1]オクタン誘導体及び抗菌剤としてのその使用
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019517596A5 (enExample)
JP7216682B2 (ja) Usp30阻害剤としての1-シアノ-ピロリジン化合物
ES2727376T3 (es) Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
US12071428B2 (en) Indazole compounds as kinase inhibitors
ES2523892T3 (es) Derivados triazol y utilización de los mismos para trastornos neurológicos
CN102112467B (zh) 作为激酶抑制剂的嘧啶衍生物
ES2715325T3 (es) Derivados de 6-bencilo-6H-pirido[3.2-e][1.2.4]triazolo[1,5-c]pirimidina-5-ona y 6-bencilo-[1.2.4]triazolo[1,5-c]pteridina-5(6H)-ona como inhibidores de PDE1 para el tratamiento, p. ej. trastornos neurológicos
JP2024513881A (ja) オキサゼピン化合物及びがんの治療におけるその使用
BR112021008986A2 (pt) composto, composto da fórmula, composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratar o câncer, para regular a atividade de uma proteína mutante g12c k-ras, para inibir a proliferação de uma população de células, para tratar um distúrbio mediado, para preparar uma proteína e para inibir metástase de tumor e uso
JP2022531801A (ja) フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法
HRP20240293T1 (hr) Derivati kinazolina kao protutumorska sredstva
CN108430993A (zh) Tank-结合激酶抑制剂化合物
KR20190091537A (ko) C-kit 억제제로서의 아미노티아졸 화합물
JP2017530999A5 (enExample)
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
AU2010286569A1 (en) Compounds and compositions as protein kinase inhibitors
JP7250011B2 (ja) P2x3阻害剤としての新規なピラゾロ-ピロロ-ピリミジン-ジオン誘導体
JP2017532360A5 (enExample)
AU2016270373A1 (en) Triazoles for the treatment of demyelinating diseases
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
JP2025540958A (ja) 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
JPWO2020057511A5 (enExample)
WO2017157792A1 (en) Combinations of copanlisib
JP7651590B2 (ja) アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用
WO2020203610A1 (ja) 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用